Use of psychotropic drugs during pregnancy and breast-feeding

Acta Psychiatrica Scandinavica

Volumn 132, Issue , 2015, Pages 1-28

  Larsen, E R ^a   Damkier, P ^b   Pedersen, L H ^a   Fenger Gron, J ^c   Mikkelsen, R L ^d   Nielsen, R E ^e   Linde, V J ^d   Knudsen, H E D ^f   Skaarup, L ^a   Videbech, P ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c KOLDING HOSPITAL   (Denmark)

^d Rigshospitalet   (Denmark)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f Psychiatric Center   (Denmark)

Author keywords

Breast feeding; Clinical guidelines; Pregnancy; Psychotropic drugs; Recommendations

Indexed keywords

AGOMELATINE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; HYPNOTIC AGENT; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; OLANZAPINE; PERPHENAZINE; PREGABALIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VALPROIC ACID; VORTIOXETINE;

ABDOMINAL PAIN; ARTICLE; ASCERTAINMENT BIAS; BIPOLAR DISORDER; BRAIN DEVELOPMENT; BRAIN HEMORRHAGE; BREAST FEEDING; CITATION BIAS; CLINICAL PRACTICE; CONGENITAL DISORDER; CONGENITAL MALFORMATION; CONSENSUS DEVELOPMENT; DEPRESSION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EMOTIONAL DEVELOPMENT; EPILEPTIC STATE; FEMALE; FETUS DEVELOPMENT; GREAT VESSELS TRANSPOSITION; HEALTH PRACTITIONER; HEART ARRHYTHMIA; HEMATURIA; HUMAN; LABOR COMPLICATION; MEDICAL SOCIETY; MENTAL DEVELOPMENT; MENTAL DISEASE; OBSTETRICS; PATIENT COUNSELING; PEDIATRICS; PERITONITIS; PERSISTENT PULMONARY HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PUBLISHING; RECALL BIAS; RECURRENCE RISK; SCHIZOPHRENIA; SEIZURE; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC ERROR; TERATOGENICITY; VAGINA BLEEDING; CHEMICALLY INDUCED; MENTAL DISORDERS; PREGNANCY COMPLICATIONS; PSYCHOLOGY;

FEMALE; HUMANS; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS;

EID: 84941041123     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12479     Document Type: Article

References (141)

1. Jimenez-Solem E, Andersen JT, Petersen M et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2:55-58.
2. Bjorn AM, Norgaard M, Hundborg HH, Nohr EA, Ehrenstein V. Use of prescribed drugs among primiparous women: an 11-year population-based study in Denmark. Clin Epidemiol 2011;3:149-156.
3. Schardein JL. Chemically induced birth defects. Principles of teratogenesis applicable to drug and chemical exposure, 3rd edn. Abingdon: CRC Press, 2000.
4. Oakley GP Jr. Frequency of human congenital malformations. Clin Perinatol 1986;13:545-554.
5. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:1708-1712.
6. Webster WS, Freeman JA. Is this drug safe in pregnancy? Reprod Toxicol 2001;15:619-629.
7. Mitchel AA. Studies of drug-induced birth defects. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. Chichester: John Wiley & Sons, Ltd, 2006.
8. www.janusifo.se. Läkemeldel och fosterskador
9. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th edn. Baltimore, MD: Lippincott Williams & Wilkins; 2011.
10. FDA. Guidance for industry: establishing pregnancy registries. Draft Guidance 1999. http://wwwfdagov/ohrms/dockets/98fr/99262gd1pdf. 2013.
11. Koren G, Sakaguchi S, Klieger C et al. Toward improved pregnancy labelling. J Popul Ther Clin Pharmacol 2010;17:e349-e357.
12. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011;157:175-182.
13. Laronda MM, Unno K, Butler LM, Kurita T. The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero. Differentiation 2012;84:252-260.
14. Hale TW. Medications and mother's milk, 15th edn. Plano, TX: Hale Publishing, 2012.
15. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698-709.
16. Cohen LS, Altshuler LL, Harlow BL et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.
17. Grigoriadis S, VonderPorten EH, Mamisashvili L et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013;74:e321-e341.
18. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Depression during pregnancy: overview of clinical factors. Clin Drug Invest 2004;24:157-179.
19. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49:726-735.
20. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-1024.
21. Oates M. Perinatal psychiatric disorders: a leading cause of maternal morbidity and mortality. Br Med Bull 2003;67:219-229.
22. Pearson RM, Evans J, Kounali D et al. Maternal depression during pregnancy and the postnatal period: risks and possible mechanisms for offspring depression at age 18 years. JAMA Psychiatry 2013;70:1312-1319.
23. Pedersen LH, Henriksen TB, Bech BH, Licht RW, Kjaer D, Olsen J. Prenatal antidepressant exposure and behavioral problems in early childhood - a cohort study. Acta Psychiatr Scand 2013;127:126-135.
24. Sundhedsstyrelsen. Reference program for unipolar depression hos voksne. 2007.
25. Speisman BB, Storch EA, Abramowitz JS. Postpartum obsessive-compulsive disorder. J Obst Gynecol Neonatal Nurs 2011;40:680-690.
26. Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN. Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J Clin Psychiatry 2010;71:1061-1068.
27. Maina G, Albert U, Bogetto F, Vaschetto P, Ravizza L. Recent life events and obsessive-compulsive disorder (OCD): the role of pregnancy/delivery. Psychiatry Res 1999;89:49-58.
28. Udechuku A, Nguyen T, Hill R, Szego K. Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010;44:978-996.
29. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2010;121:471-479.
30. Gentile S. Pregnancy exposure to serotonin reuptake inhibitors and the risk of spontaneous abortions. CNS Spectr 2008;13:960-966.
31. Einarson A, Choi J, Einarson TR, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009;31:452-456.
32. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010;182:1031-1037.
33. Stephansson O, Kieler H, Haglund B et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54.
34. Jimenez-Solem E, Andersen JT, Petersen M et al. SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry 2013;170:299-304.
35. Kjaersgaard MI, Parner ET, Vestergaard M et al. Prenatal antidepressant exposure and risk of spontaneous abortion - a population-based study. PLoS One 2013;8:e72095.
36. Grigoriadis S, VonderPorten EH, Mamisashvili L et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry 2013;74:e293-e308.
37. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-308.
38. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011;118:111-120.
39. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-1733.
40. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
41. Huybrechts KF, Palmsten K, Avorn J et al. Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 2014;370:2397-2407.
42. Huybrechts KF, Sanghani RS, Avorn J, Urato AC. Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis. PLoS One 2014;9:e92778.
43. Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV. The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age. Psychopharmacology 2013;228:199-205.
44. Moses-Kolko EL, Bogen D, Perel J et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-2383.
45. Lund N, Pedersen LH, Henriksen TB. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009;163:949-954.
46. Jensen HM, Gron R, Lidegaard O, Pedersen LH, Andersen PK, Kessing LV. Maternal depression, antidepressant use in pregnancy and Apgar scores in infants. Br J Psychiatry 2013;202:347-351.
47. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-1132.
48. Kieler H, Artama M, Engeland A et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012;344:d8012.
49. Grigoriadis S, Vonderporten EH, Mamisashvili L et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014;348:f6932.
50. El Marroun H, Jaddoe VW, Hudziak JJ et al. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012;69:706-714.
51. Knickmeyer RC, Meltzer-Brody S, Woolson S et al. Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure. Neuropsychopharmacology 2014 Oct;39(11):2611-21. doi: 10.1038/npp.2014.114. Epub 2014 May 20.
52. Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review. J Affect Disord 2011;128:1-9.
53. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600-e608.
54. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104-1112.
55. Sorensen MJ, Gronborg TK, Christensen J et al. Antidepressant exposure in pregnancy and risk of autism spectrum disorders. Clin Epidemiol 2013;5:449-459.
56. Einarson A, Fatoye B, Sarkar M et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-1730.
57. Yaris F, Kadioglu M, Kesim M et al. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19:235-238.
58. Reis M, Kallen B. Combined use of selective serotonin reuptake inhibitors and sedatives/hypnotics during pregnancy: risk of relatively severe congenital malformations or cardiac defects. A register study. BMJ Open 2013 Feb 19;3(2). pii: e002166. doi: 10.1136/bmjopen-2012-002166. Print 2013.
59. Hoog SL, Cheng Y, Elpers J, Dowsett SA. Duloxetine and pregnancy outcomes: safety surveillance findings. Int J Med Sci 2013;10:413-419.
60. Einarson A, Smart K, Vial T et al. Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report. J Clin Psychiatry 2012;73:1471.
61. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-613.
62. Newport DJ, Ritchie JC, Knight BT, Glover BA, Zach EB, Stowe ZN. Venlafaxine in human breast milk and nursing infant plasma: determination of exposure. J Clin Psychiatry 2009;70:1304-1310.
63. Djulus J, Koren G, Einarson TR et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67:1280-1284.
64. Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine-chloropyramine. Lancet 1973;2:282-284.
65. Nonacs R, Cohen LS. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002;63(Suppl 7):24-30.
66. Nulman I, Rovet J, Stewart DE et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262.
67. Viguera AC, Whitfield T, Baldessarini RJ et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007;164:1817-1824; quiz 923.
68. Appleby L, Mortensen PB, Faragher EB. Suicide and other causes of mortality after post-partum psychiatric admission. Br J Psychiatry 1998;173:209-211.
69. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002;63(Suppl 4):42-55.
70. Spinelli MG. Maternal infanticide associated with mental illness: prevention and the promise of saved lives. Am J Psychiatry 2004;161:1548-1557.
71. Yonkers KA, Wisner KL, Stowe Z et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-620.
72. EMA. PRAC recommends strengthening the restrictions on use of valproate in women and girls. EMA/612389/2014. www.emaeuropa.eu. 2014.
73. Maudsley T. The Maudsley prescribing guidelines in psychiatry, 11th edn. D. Taylor (ed.), C. Paton, S. Kapur (Co-eds). West Sussex: Wiley-Blackwell, 2012.
74. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;69:652-658.
75. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013;14:154-219.
76. Munk-Olsen T, Laursen TM, Mendelson T, Pedersen CB, Mors O, Mortensen PB. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry 2009;66:189-195.
77. Harlow BL, Vitonis AF, Sparen P, Cnattingius S, Joffe H, Hultman CM. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations. Arch Gen Psychiatry 2007;64:42-48.
78. Jacobson SJ, Jones K, Johnson K et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-533.
79. Cohen LS, Friedman JM, Jefferson JW, Johnson EM, Weiner ML. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150.
80. Diav-Citrin O, Shechtman S, Tahover E et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014;171:785-794.
81. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012;379:721-728.
82. Czeizel A, Racz J. Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology 1990;42:505-512.
83. Gentile S. Lithium in pregnancy: the need to treat, the duty to ensure safety. Exp Opin Drug Saf 2012;11:425-437.
84. Tomson T, Battino D, Bonizzoni E et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609-617.
85. Sabers A, Dam M, A-Rogvi-Hansen B et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004;109(1):9-13.
86. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-960.
87. Holmes LB, Baldwin EJ, Smith CR et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-2158.
88. Goodwin FK, Jamison KR. Manic-depressive illness. Bipolar disorders and recurrent depression. Cary, NC: Oxford University Press, 2007.
89. Morrow J, Russell A, Guthrie E et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198.
90. Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013;54:405-414.
91. de Haan GJ, Edelbroek P, Segers J et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004;63:571-573.
92. Li Z, Gindler J, Wang H et al. Folic acid supplements during early pregnancy and likelihood of multiple births: a population-based cohort study. Lancet 2003;361:380-384.
93. Christensen J, Gronborg TK, Sorensen MJ et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013;309:1696-1703.
94. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000;61:79-90.
95. Pacchiarotti I, Bond DJ, Baldessarini RJ et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-1262.
96. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. J Psychiatr Pract 2009;15:183-192.
97. Miller LJ, Finnerty M. Sexuality, pregnancy, and childrearing among women with schizophrenia-spectrum disorders. Psychiatr Serv 1996;47:502-506.
98. Coverdale JH, Bayer TL, McCullough LB, Chervenak FA. Respecting the autonomy of chronic mentally ill women in decisions about contraception. Hosp Community Psychiatry 1993;44:671-674.
99. Desai G, Chandra PS. Ethical issues in treating pregnant women with severe mental illness. Indian J Med Ethics 2009;6:75-77.
100. Lin HC, Chen IJ, Chen YH, Lee HC, Wu FJ. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res 2010;116:55-60.
101. Matevosyan NR. Pregnancy and postpartum specifics in women with schizophrenia: a meta-study. Arch Gynecol Obstet 2011;283:141-147.
102. Kohen D. Psychotropic medication in pregnancy. Adv Psychiatr Treat 2004;10:59-66.
103. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, Levinson A, Zipursky RB, Einarson, A. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005;66:444-449; quiz 546.
104. Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008;192:333-337.
105. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr Bull 2010;36:518-544.
106. Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 2013;14:38.
107. Vemuri MP, Rasgon NL. A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain. J Clin Psychiatry 2007;68:1989.
108. Habermann F, Fritzsche J, Fuhlbruck F et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol 2013;33:453-462.
109. Kulkarni J, Worsley R, Gilbert H et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One 2014;9:e94788.
110. Barnas C, Bergant A, Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994;151:945.
111. Diav-Citrin O, Shechtman S, Ornoy S et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005;66:317-322.
112. Olesen OV, Bartels U, Poulsen JH. Perphenazine in breast milk and serum. Am J Psychiatry 1990;147:1378-1379.
113. Vial TBN, Carlier P, Jonville-Bera A et al. Pregnancy outcome after first trimester exposure to zolpidem and zopiclone: a comparative cohort study. Fundam Clin Pharmacol 2011;25:pp102.
114. Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1203-1210.
115. Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am J Obstet Gynecol 2009;201:579.e1-579.e8.
116. Enato E, Moretti M, Koren G. The fetal safety of benzodiazepines: an updated meta-analysis. J Obstet Gynaecol Can 2011;33:46-48.
117. Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013;35:3-8.
118. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39-49.
119. Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol 2004;26:593-598.
120. Gidai J, Acs N, Banhidy F, Czeizel AE. Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam. Pharmacoepidemiol Drug Saf 2010;19:175-182.
121. Ban L, West J, Gibson JE et al. First trimester exposure to anxiolytic and hypnotic drugs and the risks of major congenital anomalies: a United Kingdom population-based cohort study. PLoS One 2014;9:e100996.
122. Buckley SJ. Drugs in labor: an overview. Midwifery Today Int Midwife 2004;71:13-20, 65, 67.
123. Thomsen PH, Damm D. Et liv i kaos (A life in chaos). 2. udgave. Copenhagen: Hans Reitzels Forlag, 2011.
124. Pottegard A, Hallas J, Andersen JT et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry 2014;75:e88-e93.
125. Anderson EL, Reti IM. ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosom Med 2009;71:235-242.
126. Mankad MV, Beyer JL, Weiner RD, Krystal AD. Clinical manual of electroconvulsive therapy. Arlington, VA: American Psychiatric Publishing, Inc., 2010.
127. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-450.
128. APA. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. A Task Force Report of the American Psychiatric Association. 2nd edn, Arlington, VA: American Psychiatric Association, 2001.
129. Koren G, Nickel S. Sources of bias in signals of pharmaceutical safety in pregnancy. Clin Invest Med 2010;33:E349-E355.
130. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;339:b2680.
131. Callaham M, Wears RL, Weber E. Journal prestige, publication bias, and other characteristics associated with citation of published studies in peer-reviewed journals. JAMA 2002;287:2847-2850.
132. Koren G, Nickel C. Perpetuating fears: bias against the null hypothesis in fetal safety of drugs as expressed in scientific citations. J Popul Ther Clin Pharmacol 2011;18:e28-e32.
133. Koren G. The effect of ascertainment bias in evaluating gestational antidepressant exposure. J Popul Ther Clin Pharmacol 2011;18:e174-e175.
134. EMA. A guideline on summary of product characteristics (SmPC) revision II. www.emaeuropa.eu 2012.
135. Greenwood K. The mysteries of pregnancy: the role of law in solving the problem of unknown but knowable maternal-fetal medication. Univ Cincinnati Law Rev 2011;79:266-324.
136. Brent R. Bendectin and birth defects: hopefully, the final chapter. Birth Defects Res A Clin Mol Teratol 2003;67:79-87.
137. EMA. Guideline on the exposure to medicinal products during pregnancy: need for post authorization data. EMEA/CHMP/3313666/2005. www.emaeuropa.eu 2013.
138. EMA. Guideline on risk assessment of medical products on human reproduction and lactation: from data to labeling. EMEA/CHMP/203927/2005. www.emaeuropa.eu 2013.
139. Lundbeck AS. Cipramil, produktresume. www.produktresume.dk 2013.
140. Lundbeck AS. Citalopram "Alternova", produktresume. www.produktresume.dk 2013.
141. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-2692.